A5061665880- Glioma Diagnosis and Treatment
- Brain Metastases and Treatment
- Meningioma and schwannoma management
- Vascular Malformations Diagnosis and Treatment
- CNS Lymphoma Diagnosis and Treatment
- Neuroblastoma Research and Treatments
- Lymphoma Diagnosis and Treatment
- Testicular diseases and treatments
- Fetal and Pediatric Neurological Disorders
- MRI in cancer diagnosis
- Advanced Neuroimaging Techniques and Applications
- Advanced MRI Techniques and Applications
- Cancer-related molecular mechanisms research
- Epigenetics and DNA Methylation
- Chromatin Remodeling and Cancer
- Head and Neck Surgical Oncology
- Radiopharmaceutical Chemistry and Applications
- Teratomas and Epidermoid Cysts
- Management of metastatic bone disease
- Cancer Cells and Metastasis
- Adrenal and Paraganglionic Tumors
- Intracerebral and Subarachnoid Hemorrhage Research
- Histone Deacetylase Inhibitors Research
- Growth Hormone and Insulin-like Growth Factors
- Renal cell carcinoma treatment
Hiroshima University
2019-2025
Hiroshima University Hospital
2019-2024
Tokyo Women's Medical University
2019
The WHO classification of central nervous system tumors (5th edition) classified astrocytoma, IDH-mutant accompanied with CDKN2A/B homozygous deletion as grade 4. Loss immunohistochemical (IHC) staining for methylthioadenosine phosphorylase (MTAP) was developed a surrogate marker CDKN2A-HD. Identification imaging biomarkers CDKN2A status is immense clinical relevance. In this study, we explored the association between radiological characteristics non-enhancing to status.
Abstract Purpose The T2-FLAIR mismatch sign is a highly specific diagnostic imaging biomarker for astrocytoma, IDH-mutant. However, definitive prognostic has yet to be identified. This study investigated markers, specifically analyzing T2-weighted and FLAIR images of this tumor. Methods We retrospectively analyzed 31 cases non-enhancing IDH-mutant treated at our institution, 30 from Cancer Genome Atlas (TCGA)/The Imaging Archive (TCIA). defined “super sign” as having significantly strong low...
Abstract Introduction The T2-FLAIR mismatch sign is a characteristic imaging biomarker for astrocytoma, isocitrate dehydrogenase (IDH)-mutant. However, investigators have provided varying interpretations of the positivity/negativity this given individual cases nature qualitative visual assessment. Moreover, MR sequence parameters also influence appearance sign. To resolve these issues, we used synthetic technique to quantitatively evaluate and differentiate astrocytoma from...
OBJECTIVE An MRI protocol for germinoma surveillance after complete remission has not been established. Moreover, the standard treatment recurrent or refractory determined. In this study, authors explored imaging characteristics of and discuss their institution’s experience with multidisciplinary malignancy. METHODS The medical records 16 patients (14 male, 2 female) 62 (52 10 without recurrence who were treated at authors’ institution between 1989 2023 retrospectively examined. Data...
<b><i>Introduction:</i></b> The interaction of K27M mutation in histone H3 (H3K27M mutation) with polycomb repressive complex 2 (PRC2) is facilitated by the enhancer zeste homolog (EZH2). Subsequently, this leads to global reduction level H3K27me3. We analyzed EZH2 expression H3K27M mutation-positive tumors and revealed association high poor survival. <b><i>Methods:</i></b> Our study included 12 patients, an age range 6–56 years treated between...
Abstract Background This study aimed to investigate what treatment are selected for malignant brain tumors, particularly glioblastoma (GBM) and primary central nervous system lymphoma (PCNSL), in real-world Japan the costs involved. Methods We conducted a questionnaire survey regarding selections newly diagnosed GBM PCNSL treated between July 2021 June 2022 among 47 institutions Clinical Oncology Group-Brain Tumor Study Group. calculated total cost per month of initial therapy or PCNSL....
Abstract BACKGROUND Tirabrutinib is a second-generation, highly selective oral Bruton’s tyrosine kinase inhibitor and approved for the treatment of recurrent/refractory primary central nervous system lymphoma (PCNSL) in Japan. We reviewed our single institution experiments tirabrutinib. MATERIALS AND METHODS Our institutional review board this retrospective study. Twenty-eight patients with recurrent or refractory PCNSL treated tirabrutinib at between 2020 2024 were included. Information...
Purpose: The T2-fluid-attenuated inversion recovery (FLAIR) mismatch sign was previously reported as a diagnostic indicator of diffuse astrocytoma, isocitrate dehydrogenase-mutant, and 1p/19q noncodeletion. Subsequently, it that the same findings were observed in intrinsic pontine glioma (DIPG). We investigated clinical significance T2-FLAIR DIPG. Methods: Twenty-one patients with DIPG (Male: Female = 12:9) treated at our institute between 2004 2019. All local radiotherapy 54 Gy/30...
Abstract Background Bevacizumab improves symptoms via reducing the peritumoral edema and/or normalizing blood brain barrier, and occasionally tumor size. However, effect against active cystic components has not been documented yet. Materials Methods Between 2008 2018, 139 patients with primary or metastatic tumors were treated bevacizumab (BEV) in our institution. The images before after administration of BEV examined, changes size cysts evaluated as follows: CR (complete disappearance), PR...
Dural dryness makes suturing difficult during dural closure after craniotomy. In this case, plasty is often performed using a membrane taken from the surrounding tissue (e.g., fascia or periosteum) an artificial replacement membrane. Herein, we introduce our novel "roll-up technique" to reduce utilization of substitute membranes and explore its effectiveness in closure. We retrospectively examined medical records 50 patients who underwent craniotomy for first time supratentorial intracranial...
The EF-14 clinical trial demonstrated the safety and efficacy of tumor-treating fields (TTFields) for newly diagnosed glioblastoma. This study aimed to clarify current status, safety, TTFields in Japanese patients who meet inclusion criteria.
Abstract Background H3 histone 27 lysine (H3K27) trimethylation (H3K27me3), which is catalyzed by enhancer of zeste homolog 2 (EZH2), regulates gene expression through epigenetic mechanisms. H3K27me3 used as a diagnostic marker for diffuse midline glioma and surrogate to distinguish posterior fossa ependymoma A B. However, the clinical significance EZH2–H3K27me3 axis in astrocytoma, IDH-mutant has not been reported, prompting this investigation. Methods Thirty-three patients with treated at...
Older patients represent a unique and vulnerable subgroup, requiring careful consideration when determining treatment options. Treatment-related leukoencephalopathy is commonly observed in older months to years after receiving radiotherapy and/or methotrexate for primary central nervous system lymphoma (PCNSL). Tirabrutinib an orally available, highly selective, potent second-generation Bruton's tyrosine kinase inhibitor (BTKi) approved treating recurrent/refractory PCNSL Japan. However,...